Why Diverse Clinical Trial Participation Matters | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …

Global health actors use economic evaluations, including cost-effectiveness analyses, to
estimate the effect of different interventions they might fund. However, producing reliable …

Numerous cancer therapies have detrimental cardiovascular effects on cancer survivors.
Cardiovascular toxicity can span the course of cancer treatment and is influenced by several …

Randomized controlled trials (RCTs) are often run in settings with many subpopulations that
may have differential benefits from the treatment being evaluated. We consider the problem …

We examine why minority and poor households are often underrepresented in studies that
require active participation. Using data from a serological study with randomized …

This paper cautions secondary use of data for equity and inclusion research without careful
consideration of original sampling protocols. We document large variations in women …

This review organizes the vibrant recent literature on the cognitive foundations of economic
decision-making. At a basic level, this entire literature studies imperfections in information …

We analyze representativeness in a COVID-19 serological study with randomized
participation incentives. We find large participation gaps by race and income when …

Underrepresentation of minority and poor households in scientific studies undermines policy
decisions and public health. We study data from a serological study that randomized …

Across fields, the quantity of research has increased substantially, without an attendant
increase in output. We argue that, in medicine, this indicator of declining productivity reflects …